View daily updates and historical trends for New Jersey Coronavirus Cases Currently Hospitalized. Source: US Department of Health & Human Services. Track …

A feature layer view used in the Community Impact Dashboard to view current case information.

A feature layer used to store number of COVID-19 cases for Burlington County, NJ. Note: Recovered & Active data is not accurate for cases reported after April 21, 2020. After April 21, 2020, only Confirmed, Deaths and New is accurate. This is due to a change in what the County reported. Recovered cases ceased to be reported as of April 21 which also prevented the calculation of Active cases. In all cases, Tested cases were entered as the same number as confirmed cases because no other data was available.

The counties of Trousdale and Lake – both in Tennessee – had the highest COVID-19 infection rates in the United States as of June 9, 2020. Dakota, Nobles, and Lincoln also ranked among the U.S. counties with the highest number of coronavirus cases per 100,000 people.

Coronavirus hits the East Coast In the United States, the novel coronavirus had infected around 5.4 million people and had caused nearly 170,000 deaths by mid-August 2020. The densely populated states of New York and New Jersey were at the epicenter of the outbreak in the country. New York City, which is composed of five counties, was one of the most severely impacted regions. However, the true level of transmission is likely to be much higher because many people will be asymptomatic or suffer only mild symptoms that are not diagnosed.

All states are in crisis The first coronavirus case in the U.S. was confirmed in the state of Washington in mid-January 2020. At the time, it was unclear how the virus was spreading; we now know that close contact with an infected person and breathing in their respiratory droplets is the primary mode of transmission. It is no surprise that the four states with the most coronavirus cases are those with the highest populations: New York, Texas, Florida, and California. However, Louisiana was the state with the highest COVID-19 infection rate per 100,000 people as of August 24, 2020.

Hotline numbers: 1-800-222-1222 or 1-800-962-1253 if using out-of-state phone line.

COVID-2019 is a respiratory infection caused by a novel (new) virus that arose from the area of Wuhan, China in December, 2019. Most of the early cases of this illness were linked to a large seafood and animal market suggesting possible animal-to-person spread of the virus. The market closed on January 2, 2020 as part of the investigation and response to this outbreak. Once a person is infected, the virus causes respiratory illness. Outbreaks of novel virus infections among people are always of public health concern. The risk from these outbreaks depends on the characteristics of the virus, including how well it spreads between people, the severity of the resulting illness, and the medical or other measures available to control the impact of the virus (for example, medications or vaccines).

The coronavirus disease 2019 (COVID-19) has been reported in every U.S. state, with the states of New York, New Jersey, and Michigan reporting the highest number of cases. As of April 27, 2020, there had been 119 cases of COVID-19 connected to a community in New Rochelle, New York. This statistic shows the number of cases of COVID-19 in the United States as of April 27, 2020, by place of contraction. COVID-19 is caused by the coronavirus SARS-CoV-2.

The New York Times is releasing a series of data files with cumulative counts of coronavirus cases in the United States, at the state and county level, over time. We are compiling this time series data from state and local governments and health departments in an attempt to provide a complete record of the ongoing outbreak.

Since late January, The Times has tracked cases of coronavirus in real time as they were identified after testing. Because of the widespread shortage of testing, however, the data is necessarily limited in the picture it presents of the outbreak.

We have used this data to power our maps and reporting tracking the outbreak, and it is now being made available to the public in response to requests from researchers, scientists and government officials who would like access to the data to better understand the outbreak.

The data begins with the first reported coronavirus case in Washington State on Jan. 21, 2020. We will publish regular updates to the data in this repository.

As of March 10, 2023, the state with the highest rate of COVID-19 cases was Rhode Island followed by Alaska. Around 103.9 million cases have been reported across the United States, with the states of California, Texas, and Florida reporting the highest numbers of infections.

From an epidemic to a pandemic The World Health Organization declared the COVID-19 outbreak as a pandemic on March 11, 2020. The term pandemic refers to multiple outbreaks of an infectious illness threatening multiple parts of the world at the same time; when the transmission is this widespread, it can no longer be traced back to the country where it originated. The number of COVID-19 cases worldwide is roughly 683 million, and it has affected almost every country in the world.

The symptoms and those who are most at risk Most people who contract the virus will suffer only mild symptoms, such as a cough, a cold, or a high temperature. However, in more severe cases, the infection can cause breathing difficulties and even pneumonia. Those at higher risk include older persons and people with pre-existing medical conditions, including diabetes, heart disease, and lung disease. Those aged 85 years and older have accounted for around 27 percent of all COVID deaths in the United States, although this age group makes up just two percent of the total population

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Updated (Bivalent) Booster Status. Click 'More' for important dataset description and footnotes

Webpage: https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status

Dataset and data visualization details:

These data were posted and archived on May 30, 2023 and reflect cases among persons with a positive specimen collection date through April 22, 2023, and deaths among persons with a positive specimen collection date through April 1, 2023. These data will no longer be updated after May 2023.

Vaccination status: A person vaccinated with at least a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. A person vaccinated with a primary series and a monovalent booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and at least one additional dose of any monovalent FDA-authorized or approved COVID-19 vaccine on or after August 13, 2021. (Note: this definition does not distinguish between vaccine recipients who are immunocompromised and are receiving an additional dose versus those who are not immunocompromised and receiving a booster dose.) A person vaccinated with a primary series and an updated (bivalent) booster dose had SARS-CoV-2 RNA or antigen detected in a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and an additional dose of any bivalent FDA-authorized or approved vaccine COVID-19 vaccine on or after September 1, 2022. (Note: Doses with bivalent doses reported as first or second doses are classified as vaccinated with a bivalent booster dose.) People with primary series or a monovalent booster dose were combined in the “vaccinated without an updated booster” category.

Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Per the interim guidance of the Council of State and Territorial Epidemiologists (CSTE), this should include persons whose death certificate lists COVID-19 disease or SARS-CoV-2 as the underlying cause of death or as a significant condition contributing to death. Rates of COVID-19 deaths by vaccination status are primarily reported based on when the patient was tested for COVID-19. In select jurisdictions, deaths are included that are not laboratory confirmed and are reported based on alternative dates (i.e., onset date for most; or date of death or report date, where onset date is unavailable). Deaths usually occur up to 30 days after COVID-19 diagnosis.

Participating jurisdictions: Currently, these 24 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Colorado, District of Columbia, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (NY), North Carolina, Rhode Island, Tennessee, Texas, Utah, and West Virginia; 23 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 48% of the total U.S. population and all ten of the Health and Human Services Regions. This list will be

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status.

Click 'More' for important dataset description and footnotes

Dataset and data visualization details:

These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected.

Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type.

** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group.

Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis.

Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases

Splitgraph serves as an HTTP API that lets you run SQL queries directly on this data to power Web applications. For example:

See the Splitgraph documentation for more information.

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases

As of March 10, 2023, the death rate from COVID-19 in the state of New York was 397 per 100,000 people. New York is one of the states with the highest number of COVID-19 cases.

Feature layer generated from Join Features to show number of deaths from COVID 19 for Burlington County, NJ.

As of March 10, 2023, there have been 1.1 million deaths related to COVID-19 in the United States. There have been 101,159 deaths in the state of California, more than any other state in the country – California is also the state with the highest number of COVID-19 cases.

The vaccine rollout in the U.S. Since the start of the pandemic, the world has eagerly awaited the arrival of a safe and effective COVID-19 vaccine. In the United States, the immunization campaign started in mid-December 2020 following the approval of a vaccine jointly developed by Pfizer and BioNTech. As of March 22, 2023, the number of COVID-19 vaccine doses administered in the U.S. had reached roughly 673 million. The states with the highest number of vaccines administered are California, Texas, and New York.

Vaccines achieved due to work of research groups Chinese authorities initially shared the genetic sequence to the novel coronavirus in January 2020, allowing research groups to start studying how it invades human cells. The surface of the virus is covered with spike proteins, which enable it to bind to human cells. Once attached, the virus can enter the cells and start to make people ill. These spikes were of particular interest to vaccine manufacturers because they hold the key to preventing viral entry.

Overview

As coronavirus cases have exploded across the country, states have struggled to obtain sufficient personal protective equipment such as masks, face shields, gloves and ventilators to meet the needs of healthcare workers. FEMA began distributing PPE from the national stockpile as well as PPE obtained from private manufacturers to states in March.

Initially, FEMA distributed materials based primarily on population. By late March, Its methods changed to send more PPE to hotspot locations, and FEMA claimed these decisions were data-driven and need-based. By late spring, the agency was considering requests from states as well.

Although all U.S. states and territories have received some amount of PPE from FEMA, the amounts of PPE states have per capita and per positive COVID-19 case vary widely.

The AP used this data in a story that ran July 7.

Findings

• Overall, low population, rural states have the most PPE per positive case as of mid-June. This generally held true across types of equipment.
• The states that had the highest number of total PPE items per coronavirus case as of mid-May were, in descending order: Alaska, Montana, Vermont, Hawaii, Wyoming, and North Dakota. The highest was Alaska with 1,579 PPE items per coronavirus case.
• The states that had the highest number of total items per case as of mid-June were largely the same states — Montana, Alaska, Hawaii, Vermont, Wyoming, and West Virginia. The highest was Montana with 1,125 PPE items per coronavirus case.
• Conversely, the states that had the lowest amounts of PPE per positive case in mid-May included hotspot states — Massachusetts, New York, Virginia, California, Nebraska, and Iowa. New Jersey was just a couple spots further down. The lowest was Massachusetts with 36 PPE items per coronavirus case.
• The states that had the lowest amounts of PPE per case as of mid-June were largely the same as well — Massachusetts, New York, Iowa, California, and Nebraska. The lowest was Massachusetts with 32 PPE items per coronavirus case.
• When evaluated on a per-capita basis rather than per positive coronavirus case, the picture is different. The District of Columbia received the most PPE per capita in both May and June, although the vast majority of the PPE it received was distributed as of mid-May. Vermont, Kansas, New Jersey, and North Dakota had the next highest numbers of PPE per capita as of both mid-May and mid-June.
• There is no clear pattern of FEMA distribution by party control of states.

About the data

These numbers include material distributed by FEMA and also those sold by private distributors under direction from FEMA. They include materials both delivered to and en route to states.

States have purchased PPE directly in addition to receiving PPE from FEMA or directed there by the agency, and this data only includes the latter categories.

FEMA also distributed and directed the distribution of gear to U.S. territories in addition to states, which are included in FEMA’s release linked below, but not are not included in this data.

FEMA has publicly distributed its breakdown of PPE delivery by state for May and June. FEMA did not provide comprehensive numbers for each state before May.

These numbers are cumulative, meaning that the numbers for May include items of PPE distributed prior to May 14, dating to when the agency began allocations on March 1. The June numbers include the May numbers and any new PPE distributions since then.

The population column, which was used to calculate the numbers of PPE items per state, came from data from the U.S Census Bureau. Since the Census releases annual population data, population data from 2019 was used for each state.

The numbers of coronavirus cases were pulled from the data released daily by Johns Hopkins University as of the dates that FEMA released its distribution numbers — May 14 and June 10.

Caveats

The data includes amounts of gear that had been delivered to the states or were en route as of the reporting dates.

All PPE item numbers above 1 million were rounded to the nearest hundred thousand by FEMA, but numbers lower than that were not rounded.

In some cases, gear headed to a state was rerouted because it was needed more somewhere else or a state decided it did not need it. In some instances, that resulted in states having higher numbers for certain supplies in May than in June.

This file contains COVID-19 death counts and rates by month and year of death, jurisdiction of residence (U.S., HHS Region) and demographic characteristics (sex, age, race and Hispanic origin, and age/race and Hispanic origin). United States death counts and rates include the 50 states, plus the District of Columbia. Deaths with confirmed or presumed COVID-19, coded to ICD–10 code U07.1. Number of deaths reported in this file are the total number of COVID-19 deaths received and coded as of the date of analysis and may not represent all deaths that occurred in that period. Counts of deaths occurring before or after the reporting period are not included in the file. Data during recent periods are incomplete because of the lag in time between when the death occurred and when the death certificate is completed, submitted to NCHS and processed for reporting purposes. This delay can range from 1 week to 8 weeks or more, depending on the jurisdiction and cause of death. Death counts should not be compared across jurisdictions. Data timeliness varies by state. Some states report deaths on a daily basis, while other states report deaths weekly or monthly. The ten (10) United States Department of Health and Human Services (HHS) regions include the following jurisdictions. Region 1: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont; Region 2: New Jersey, New York; Region 3: Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, West Virginia; Region 4: Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee; Region 5: Illinois, Indiana, Michigan, Minnesota, Ohio, Wisconsin; Region 6: Arkansas, Louisiana, New Mexico, Oklahoma, Texas; Region 7: Iowa, Kansas, Missouri, Nebraska; Region 8: Colorado, Montana, North Dakota, South Dakota, Utah, Wyoming; Region 9: Arizona, California, Hawaii, Nevada; Region 10: Alaska, Idaho, Oregon, Washington. Rates were calculated using the population estimates for 2021, which are estimated as of July 1, 2021 based on the Blended Base produced by the US Census Bureau in lieu of the April 1, 2020 decennial population count. The Blended Base consists of the blend of Vintage 2020 postcensal population estimates, 2020 Demographic Analysis Estimates, and 2020 Census PL 94-171 Redistricting File (see https://www2.census.gov/programs-surveys/popest/technical-documentation/methodology/2020-2021/methods-statement-v2021.pdf). Rate are based on deaths occurring in the specified week and are age-adjusted to the 2000 standard population using the direct method (see https://www.cdc.gov/nchs/data/nvsr/nvsr70/nvsr70-08-508.pdf). These rates differ from annual age-adjusted rates, typically presented in NCHS publications based on a full year of data and annualized weekly age-adjusted rates which have been adjusted to allow comparison with annual rates. Annualization rates presents deaths per year per 100,000 population that would be expected in a year if the observed period specific (weekly) rate prevailed for a full year. Sub-national death counts between 1-9 are suppressed in accordance with NCHS data confidentiality standards. Rates based on death counts less than 20 are suppressed in accordance with NCHS standards of reliability as specified in NCHS Data Presentation Standards for Proportions (available from: https://www.cdc.gov/nchs/data/series/sr_02/sr02_175.pdf.).

Maximum difference in the median RMSE values for the number of daily confirmed cases and the number of daily deaths for all combinations of rc and γc values for Lombardy, Emilia-Romagna, Piedmont, State of Louisiana, State of New Jersey, and the State of New York. RMSE values are provided in both in absolute values and relative to the mean of their corresponding data type. (XLSX)